Albert Robichaud - Oct 19, 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Scientific Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Albert Robichaud
Stock symbol
SAGE
Transactions as of
Oct 19, 2021
Transactions value $
-$44,964
Form type
4
Date filed
10/21/2021, 04:03 PM
Previous filing
Jun 17, 2021
Next filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +3.8K +2.72% $0.00 144K Oct 19, 2021 Direct F1, F2
transaction SAGE Common Stock Tax liability -$45K -1.12K -0.78% $40.29 143K Oct 19, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 3,800 shares.
F2 Reflects beneficial ownership balance which includes 284 shares purchased on June 30, 2021 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.